A. Margossian

Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and organoid profiling

M. Griffith, C. Grandori, G. Poultsides, 2021, medRxiv.

Predictive Biomarkers and Personalized Medicine Progesterone Receptor Isoform-Specific Promoter Methylation : Association of PRA Promoter Methylation with Worse Outcome in Breast Cancer Patients

S. Hilsenbeck, J. Issa, J. Jelinek, 2011 .

Progesterone Receptor Isoform-Specific Promoter Methylation: Association of PRA Promoter Methylation with Worse Outcome in Breast Cancer Patients

S. Hilsenbeck, J. Issa, J. Jelinek, 2011, Clinical Cancer Research.

DNA methylation as a biomarker in breast cancer.

Manfred Schmitt, Nadia Harbeck, J. Foekens, 2009, Future oncology.

Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.

J. Foekens, J. Nährig, G. Kristiansen, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive value of a CLIA-approved organoid based drug sensitivity test.

Robert L. Diaz, Shalini C. Pereira, C. Grandori, 2020 .

CHOLANGIOCARCINOMA FOUNDATION ANNUAL MEETING 2020: ABSTRACT https://cholangiocarcinoma.org/2020-annual-conference Title: ORGANOID BASED FUNCTIONAL TEST TO PREDICT PERSONALIZED TREATMENT IN CHOLANGIOCARCINOMA

Hallie A. Swan, Robert L. Diaz, Shalini C. Pereira, 2020 .

Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing

Hallie A. Swan, Robert L. Diaz, Shalini C. Pereira, 2023, NPJ precision oncology.

Multicenter study validates PITX2 DNA methylation for risk prediction in tamoxifen-treated, node-negative breast cancer using paraffin-embedded tumor tissue

G. Kristiansen, A. Paradiso, N. Harbeck, 2005 .